Novel immunotherapeutic options for BCG‐unresponsive high‐risk non‐muscle‐invasive bladder cancer

Novel immunotherapeutic options for BCG‐unresponsive high‐risk non‐muscle‐invasive bladder cancer

Abstract Background High‐risk non‐muscle‐invasive bladder cancer (HR‐NMIBC) presents a challenge to many physicians due to its ability to resist Bacillus Calmette–Guérin (BCG) intravesical therapy and the substantial rate of progression into muscle‐invasive bladder cancer (MIBC). Patients who are BC...

Full description

Bibliographic Details
Main Authors: Zein Alabdin Hannouneh, Amjad Hijazi, Alaa Aldeen Alsaleem, Siwan Hami, Nina Kheyrbek, Fadi Tanous, Karam Khaddour, Abdulfattah Abbas, Zuheir Alshehabi
Format: Article
Language:English
Published: Wiley 2023-12-01
Series:Cancer Medicine
Subjects:
Bacillus Calmette–Guérin‐unresponsive
gene therapy
immune checkpoint inhibitors
immunotherapy
non‐muscle‐invasive bladder cancer
oncolytic viral therapy
Online Access:https://doi.org/10.1002/cam4.6768

Internet

https://doi.org/10.1002/cam4.6768

Similar Items